Company Description
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States.
The company’s lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain.
It also develops PIPE-307, a novel, small-molecule inhibitor of the muscarinic type 1 receptor for depression and relapse-remitting multiple sclerosis.
The company was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023.
Contineum Therapeutics, Inc. was incorporated in 2009 and is based in San Diego, California.
| Country | United States |
| Founded | 2009 |
| IPO Date | Apr 5, 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 51 |
| CEO | Carmine Stengone |
Contact Details
Address: 3565 General Atomics Court, Suite 200 San Diego, California 92121 United States | |
| Phone | 858 333 5280 |
| Website | contineum-tx.com |
Stock Details
| Ticker Symbol | CTNM |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Share Class | Class A Shares |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 1855175 |
| CUSIP Number | 21217B100 |
| ISIN Number | US21217B1008 |
| Employer ID | 27-1467257 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Carmine N. Stengone MBA, MS | President, Chief Executive Officer and Director |
| John S. Healy | General Counsel and Corporate Secretary |
| Peter T. Slover CPA | Chief Financial Officer |
| Morgan Paulsen | Senior Manager of Accounting |
| Dr. Daniel S. Lorrain Ph.D. | Chief Science Officer |
| Steve E. Kunszabo | Senior Director of Investor Relations and Corporate Communications |
| Jennifer Patterson | Vice President of Human Resources |
| Austin Chen Ph.D. | Senior Vice President and Head of Research |
| Julie S. Iwashita | Senior Vice President of Clinical Operations |
| Dr. Timothy R. Watkins M.D., M.Sc. | Chief Medical Officer and Head of Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 5, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 5, 2026 | 424B5 | Filing |
| Mar 5, 2026 | 10-K | Annual Report |
| Mar 5, 2026 | 8-K | Current Report |
| Feb 17, 2026 | SCHEDULE 13G/A | Filing |
| Feb 17, 2026 | SCHEDULE 13G | Filing |
| Feb 17, 2026 | SCHEDULE 13G | Filing |
| Feb 11, 2026 | 144 | Filing |
| Feb 11, 2026 | 144 | Filing |
| Feb 3, 2026 | 144 | Filing |